We first covered Neurocrine Biosciences, Inc. (Nasdaq: NBIX) in late May 2010, when the stock was trading at $3.40 a share. About a week after our post, shares of NBIX climbed to a high of $5.20 a share. Neurocrine rallied again on Thursday, climbing almost 8 percent to a 52-week high of $5.79 a share in morning trading after the company announced a development deal with privately held German drug maker, Boehringer Ingelheim.
[–quote–]
The two companies will work together to research and develop small molecule GPR119 agonists for the treatment of Type II diabetes and other indications . Neurocrine will get a $10 million upfront payment and research funding to support discovery efforts. The company is also eligible to receive up to $225 million in milestone payments, according to Neurocrine.
A day before, Neurocrine licensed the worldwide rights to its experimental endometriosis drug to Abbott Laboratories. Under terms of the deal announced Wednesday, Abbott gains worldwide rights to elagolix in exchange for a $50 million upfront payment to Neurocrine. Abbott agreed to pay all future development costs for the drug. Neurocrine is eligible for up to $500 million in future milestone payments as well as royalties based on sales of elagolix if approved.

Shares of memory subsystems maker Netlist, Inc. (Nasdaq: NLST) continued their rally on Monday morning, climbing about 32 percent from Friday’s close. Shares gained about 30 percent on Friday as well, after the company announced that its HyperCloud™ memory module was been selected to run on servers owned by British IT solutions provider, Viglen to support High Performance Computing (HPC) applications.
Shares of compliance and management software maker ArcSight, Inc. (Nasdaq: ARST) were up more than 24 percent in morning trading on Friday after the company announced better-than-expected fourth quarter earnings, and painted a rosier-than-expected picture for the current quarter.
Shares of alternative energy solutions provider, Carbon Sciences, Inc. were up more than 70 percent in morning trading on Tuesday.